RCMU
NVAX icon

Rokos Capital Management (UK)’s Novavax NVAX Stock Holding History

Rokos Capital Management (UK)’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-500,000
Closed -$4.92M – 79
2022
Q4 		$4.92M Buy
+500,000
New +$8.82M 0.22% 42
2021
Q1 		– Sell
-28,925
Closed -$3.29M – 116
2020
Q4 		$3.29M Buy
+28,925
New +$3.07M 0.07% 42

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rokos Capital Management (UK)'s NVAX Position: Q1 2023 in Review

Rokos Capital Management (UK) sold out of Novavax (NVAX) in Q1 2023, closing a stake of 500,000 shares — an estimated $4.92M sold.

Rokos Capital Management (UK) first reported a position in NVAX in Q4 2020 and held it in 2 quarters. The position peaked at $4.92M in Q4 2022. 222 funds tracked by Wall St. Rank hold NVAX as of Q1 2023.

  • Rokos Capital Management (UK) reported no remaining Novavax position as of Q1 2023 after selling out during the quarter.
  • Rokos Capital Management (UK) sold 500,000 Novavax shares in Q1 2023, an estimated $4.92M.
  • Rokos Capital Management (UK) first reported a position in Novavax in Q4 2020 and held it in 2 quarters.
  • Rokos Capital Management (UK)'s Novavax position peaked at $4.92M in Q4 2022.
  • 222 funds tracked by Wall St. Rank held Novavax as of Q1 2023.

Based on Rokos Capital Management (UK)'s 13F filing for Q1 2023, filed 15 May 2023.